<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="163222">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02029196</url>
  </required_header>
  <id_info>
    <org_study_id>ITG EVP G1 S2</org_study_id>
    <nct_id>NCT02029196</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety Profile of an e-Vapour Product</brief_title>
  <official_title>A Randomised, Parallel Group, Multi-centre Study to Evaluate the Safety Profile of the ITG EVP G1 Product</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial Tobacco Group PLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imperial Tobacco Group PLC</source>
  <oversight_info>
    <authority>United Kingdom: South East Wales Research Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Electronic Vapour Products (EVPs) is a relatively new class of consumer products that are
      otherwise known as electronic cigarettes or electronic nicotine delivery devices/systems.
      These may look like conventional cigarettes but do not contain tobacco.

      The 'vapour' produced by such devices typically consists of humectants (propylene glycol or
      glycerol), nicotine, water, and flavours.

      This trial is to evaluate the safety and tolerability of an e-vapour product.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Vital signs</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>ECG</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Lung Function Testing</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical laboratory parameters</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Craving and withdrawal symptoms</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Carboxyhaemoglobin</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High-density lipoprotein cholesterol</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">420</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>e-vapour product (EVP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who switch from using conventional cigarettes to using an e-vapour product (EVP).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional cigarette (CC)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects who continue smoking their usual conventional cigarette (CC) brand.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>E-vapour product</intervention_name>
    <arm_group_label>e-vapour product (EVP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Conventional cigarette</intervention_name>
    <arm_group_label>Conventional cigarette (CC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI of 18-35kg/m2

          -  Subjects must be established smokers

          -  Subjects must have smoked five to 30 cigarettes per day for at least one year

        Exclusion Criteria:

          -  Subjects who have used nicotine replacement therapy within 14 days of the screening

          -  Subjects who have donated blood within 12 months preceding study

          -  Subjects with relevant illness history

          -  Subjects positive for hepatitis or HIV

          -  Subjects with history of drug or alcohol abuse

          -  Subjects with lung function test or vital signs considered unsuitable

          -  Subjects who are trying to stop smoking

          -  Female subjects who are pregnant, or unwilling to use acceptable contraceptive method
             for the duration of the study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jim Bush, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance Clinical Research Unit, Springfield House, Hyde Street, Leeds LS2 9LH, UK</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Girish Sharma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Simbec Research, Merthyr Tydfil, CF48 4DR, UK</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robert Turner-Cain, BA, MBA</last_name>
    <phone>+44 (0)113 2373500</phone>
    <phone_ext>2130</phone_ext>
    <email>robert.turner_cain@covance.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Oliver Knott, MSc</last_name>
    <phone>+44 (0)1443 694317</phone>
    <email>oliver.knott@simbec.co.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Covance Clinical Research Unit</name>
      <address>
        <city>Leeds</city>
        <state>England</state>
        <zip>LS2 9HL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Turner-Cain, BA, MBA</last_name>
      <phone>+44 (0)113 2373500</phone>
      <phone_ext>2130</phone_ext>
      <email>robert.turner_cain@convance.com</email>
    </contact>
    <investigator>
      <last_name>Jim Bush, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Simbec Research</name>
      <address>
        <city>Merthyr Tydfil</city>
        <state>Wales</state>
        <zip>CF48 4DR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oliver Knott, MSc</last_name>
      <phone>+44 (0) 1443 694317</phone>
      <email>oliver.knott@simbec.co.uk</email>
    </contact>
    <investigator>
      <last_name>Girish Sharma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 6, 2014</lastchanged_date>
  <firstreceived_date>December 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
